Live Chat
0 ITEMS0

0 ITEMS

৳
0
Dhaka

Selected City: Dhaka

Use my current Location


Change City

EN 

|

 বাং

Dhaka

Use my current Location


Change City

Selected City: Dhaka

Grocery
Pharmacy
Cookups
  • Offers
  • Egg Club
  • Daily Deals
  • Favourites
  • Common Conditions 
  • Sexual Wellness
  • Birth Control Contraceptives
  • Vitamins & Supplements 
  • Medical Devices
  • Medical Accessories
  • Personal Care 
  • Health & Wellness 
  • Baby Care 
  • Premium Care
  • Food Aid
  • Recipes
Help
File a complaint

    Axicef Tablet 250mg

    4 tablets
    ৳100
    0
    in bag

    Product Information

    AXICEF

    Axicef ®

    (Cefuroxime Axetil )

    Presentation

    Axicef 250 tablet: White, capsule shaped, breakline on one side, film coated tablet; each tablet contains Cefuroxime Axetil BP

    equivalent to Cefuroxime 250 mg

    Axicef 500 tablet: White, capsule shaped, film coated tablet; each tablet contains Cefuroxime Axetil BP equivalent to Cefuroxime

    500 mg

    Axicef suspension: White, Tutti-frutti flavoured powder for Suspension; after reconstitution each 5 ml suspension contains

    Cefuroxime Axetil BP equivalent to Cefuroxime 125 mg

    Indication

    Axicef (Cefuroxime Axetil) is Indicated for the treatment of Acute streptococcal tonsillitis and pharyngitis, Acute bacterial

    sinusitis, Acute otitis media, Acute exacerbations of chronic bronchitis, Cystitis, Pyelonephritis, Uncomplicated skin and soft

    tissue infections & early Lyme disease in adults and children (³3 months)

    Dosage and Administration

    The usual course of Axicef (Cefuroxime Axetil) is seven days (may range from five to ten days).

    table 1 [https://unimedunihealth.com/wp-content/uploads/2017/07/table-1-119x300.jpg]

    [https://unimedunihealth.com/wp-content/uploads/2017/07/table-1.jpg]

    There is no experience of using  Axicef (Cefuroxime Axetil) in children under the age of 3 months.

    Renal impairment: The safety and efficacy of Axicef (Cefuroxime Axetil) in patients with renal failure have not been established.

    Axicef (Cefuroxime Axetil) is primarily excreted by the kidneys. In patients with markedly impaired renal function it is

    recommended that the dosage of Axicef (Cefuroxime Axetil) should be reduced to compensate for its slower excretion. Axicef

    (Cefuroxime Axetil) is effectively removed by dialysis.

    table 2 [https://unimedunihealth.com/wp-content/uploads/2017/07/table-2-300x235.jpg]

    [https://unimedunihealth.com/wp-content/uploads/2017/07/table-2.jpg]

    Hepatic impairment: There are no data available for patients with hepatic impairment. Since Axicef (Cefuroxime Axetil)is primarily

    eliminated by the kidney, the presence of hepatic dysfunction is expected to have no effect on the pharmacokinetics of Axicef

    (Cefuroxime Axetil).

    Method of administration: Oral use: Axicef (Cefuroxime Axetil) tablets should be taken after food for optimum absorption.

    Contra-indication, warnings etc

    Contra-indication: Patients with known hypersensitivity to cephalosporin antibiotics. History of severe hypersensitivity to any

    other type of betalactam antibacterial agent (penicillins, monobactams and carbapenems).

    Warnings and precautions: Hypersensitivity reactions: Special care is indicated in patients who have experienced an allergic

    reaction to penicillins or other beta-lactam antibiotics because there is a risk of cross-sensitivity. As with all beta-lactam

    antibacterial agents, serious and occasionally fatal hypersensitivity reactions have been reported. In case of severe

    hypersensitivity reactions, treatment with cefuroxime must be discontinued immediately and adequate emergency measures must be

    initiated. Before beginning treatment, it should be established whether the patient has a history of severe hypersensitivity

    reactions to cefuroxime, to other cephalosporins or to any other type of beta-lactam agent. Caution should be used if cefuroxime

    is given to patients with a history of non-severe hypersensitivity to other beta-lactam agents. Jarisch-Herxheimer reaction: The

    Jarisch-Herxheimer reaction has been seen following cefuroxime axetil treatment of Lyme disease. It results directly from the

    bactericidal activity of cefuroxime axetil on the causative bacteria of Lyme disease, the spirochaete Borrelia burgdorferi.

    Patients should be reassured that this is a common and usually self-limiting consequence of antibiotic treatment of Lyme disease.

    Overgrowth of non-susceptible microorganisms: As with other antibiotics, use of cefuroxime Axetil may result in the overgrowth of

    Candida. Prolonged use may also result in the overgrowth of other non-susceptible microorganisms (e.g. enterococci and Clostridium

    difficile), which may require interruption of treatment. Antibacterial agent-associated pseudomembranous colitis have been

    reported with nearly all antibacterial agents, including cefuroxime and may range in severity from mild to life threatening. This

    diagnosis should be considered in patients with diarrhoea during or subsequent to the administration of cefuroxime.

    Discontinuation of therapy with cefuroxime and the administration of specific treatment for Clostridium difficile should be

    considered. Medicinal products that inhibit peristalsis should not be given. Interference with diagnostic tests: The development

    of a positive Coomb’s Test associated with the use of cefuroxime may interfere with cross matching of blood. As a false negative

    result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to

    determine blood/plasma glucose levels in patients receiving cefuroxime Axetil.

    Drug Interactions: Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with

    that of the fasting state and tend to cancel the effect of enhanced absorption after food. Cefuroxime is excreted by glomerular

    filtration and tubular secretion. Concomitant use of probenecid is not recommended. Concurrent administration of probenecid

    significantly increases the peak concentration, area under the serum concentration time curve and elimination half-life of

    Cefuroxime. Concomitant use with oral anticoagulants may give rise to increased INR.

    Use in pregnancy and lactation: Pregnancy: Pregnancy category B. There are limited data from the use of cefuroxime in pregnant

    women. Studies in animals have shown no harmful effects on pregnancy, embryonal or foetal development, parturition or postnatal

    development. Cefuroxime Axetil should be prescribed to pregnant women only if the benefit outweighs the risk. Breastfeeding:

    Cefuroxime is excreted in human milk in small quantities. Adverse effects at therapeutic doses are not expected, although a risk

    of diarrhoea and fungus infection of the mucous membranes cannot be excluded. Breastfeeding might have to be discontinued due to

    these effects. The possibility of sensitisation should be taken into account. Cefuroxime should only be used during breastfeeding

    after benefit/risk assessment by the physician in charge. Fertility: There are no data on the effects of Cefuroxime Axetil on

    fertility in humans. Reproductive studies in animals have shown no effects on fertility.

    Effects on ability to drive and use machines: No studies on the effects on the ability to drive and use machines have been

    performed. However, as this medicine may cause dizziness, patients should be warned to be cautious when driving or operating

    machinery.

    Overdose: Overdose can lead to neurological sequelae including encephalopathy, convulsions and coma. Symptoms of overdose can

    occur if the dose is not reduced appropriately in patients with renal impairment. Serum levels of cefuroxime can be reduced by

    haemodialysis and peritoneal dialysis.

    Direction for reconstitution of powder for suspension: Shake the bottle well so that powder does not clog. Add 45ml (9 x 5ml

    spoonful) boiled and cooled water to the bottle. Shake well until all powder is dispersed. Reconstituted suspension should be

    stored between 20 and 80 C in  a refrigerator. Discard unused portion after 10 days. Shake the bottle well before each use.

    Pharmaceutical precautions

    Store in a cool and dry place, protected from light.

    Packaging quantities

    Axicef 250 tablet: Carton containing of 12 tablets in  alu-alu blisters.

    Axicef 500 tablet: Carton containing of 8 tablets in blisters.

    Axicef suspension: Carton containing powder to produce 70 ml suspension when reconstituted in glass bottle.

    Manufactured by

    UniMed & UniHealth Manufacturers Ltd.

    B K Bari, Gazipur, Bangladesh

    ® Registered Trademark

    • 30 minute delivery
    • Cash on delivery
    • Pay with

    Chaldal logo

    Chaldal.com is an online shop available in Dhaka, Chattogram, Jashore, Khulna and Narayanganj. We believe time is valuable to our fellow residents, and that they should not have to waste hours in traffic, brave bad weather and wait in line just to buy basic necessities like eggs! This is why Chaldal delivers everything you need right at your door-step and at no additional cost.

    Customer Service

    • Contact Us
    • FAQ

    About Chaldal

    • Privacy Policy
    • Terms of Use

    For Business

    • Corporate
    16710
    or email[email protected]